Last update : 05/05/2021 | Version : 1 | ID : 73909
| General | |
| Identification | |
| Detailed name | Study on the implementation of the revised HOME-CoV score to guide the choice of hospitalisation or outpatient management of patients with confirmed or probable SARS-CoV-2 infection admitted to an emergency department. | 
| Sign or acronym | Revised HOME-CoV | 
| CNIL registration number, number and date of CPP agreement, AFSSAPS (French Health Products Safety Agency) authorisation | 2020-A03067-32 | 
| General Aspects | |
| Medical area | Emergency medicine | 
| Study in connection with Covid-19 | Yes | 
| Health determinants | Healthcare system and access to health care services | 
| Keywords | COVID-19; Hospitalization; Outpatient; Rule validation; Expert consensus; Rule-based decision-making; Clinical support decision tool. | 
| Scientific investigator(s) (Contact) | |
| Name of the director | Douillet | 
| Surname | Delphine | 
| Address | Departement de Médecine d'Urgence<br>4 rue Larrey<br>CHU ANGERS | 
| Delphine.Douillet@chu-angers.fr | |
| Collaborations | |
| Funding | |
| Funding status | Public | 
| Details | Angers University Hospital | 
| Governance of the database | |
| Sponsor(s) or organisation(s) responsible | Angers University Hospital | 
| Organisation status | |
| Additional contact | |
| Main features | |
| Type of database | |
| Type of database | Study databases | 
| Study databases (details) | Cohort study | 
| Database recruitment is carried out by an intermediary | A selection of health institutions and services | 
| Database recruitment is is made on the basis of: | Another treatment or procedure | 
| Database recruitment is carried out as part of an interventional study | Yes | 
| Details | Performed at group level (clusters) | 
| Database objective | |
| Main objective | The primary objective is to demonstrate the reliability and safety of outpatient management among patients highly suspected or confirmed as infected with COVID-19, attending an emergency department and with a revised HOME-CoV score less than 2 (negative rule). The secondary objectives are as follows: i. Evaluate the rate of patients having required hospitalisation within 7 days following inclusion according to the revised positive or negative HOME-CoV rule. ii. Evaluate the rate of patients having required hospitalisation and initiation of oxygen therapy within 7 days following inclusion according to the revised positive or negative HOME-CoV rule. iii. Evaluate the rate of patients having required intubation within 7 days following inclusion according to the revised positive or negative HOME-CoV rule. iv. Evaluate the rate of all-cause deaths within 7 days following inclusion according to the revised positive or negative HOME-CoV rule. v. Evaluate the performance of the revised HOME-CoV score in predicting a negative outcome in the patient subgroup with SARS-CoV-2 infection confirmed by RT-PCR to rule out the risk of a negative outcome when assessed as low risk. vi. Compare the performance of the revised HOME-CoV score with that of other existing scores. | 
| Inclusion criteria | Adult patient (> 18 years), - Attending one of the emergency departments taking part in the study due to COVID-19 infection confirmed by SARS-CoV-2 positive RT-PCR, or considered highly probable by the physician managing the patient, - Not requiring management in a continuous care or intensive care unit, and subject to a decision to limit active treatment, - Having given their formal consent to take part in the study, - Registered with or a beneficiary of a social security scheme. | 
| Population type | |
| Age | Adulthood (19 to 24 years) Adulthood (25 to 44 years) Adulthood (45 to 64 years) Elderly (65 to 79 years) Great age (80 years and more) | 
| Population covered | Sick population | 
| Pathology | B33 - Other viral diseases, not elsewhere classified | 
| Gender | Male Woman | 
| Geography area | International | 
| Detail of the geography area | France Belgium | 
| Data collection | |
| Dates | |
| Size of the database | |
| Size of the database (number of individuals) | [1000-10 000[ individuals | 
| Details of the number of individuals | 1,300 patients | 
| Data | |
| Database activity | Current data collection | 
| Type of data collected | Clinical data Declarative data Paraclinical data Biological data Administrative data | 
| Clinical data (detail) | Direct physical measures Medical registration | 
| Declarative data (detail) | Face to face interview | 
| Procedures | |
| Followed pathology | |
| Promotion and access | |
| Promotion | |
| Access | 
Partners - FAQ - Contact - Site map - Legal notices - Administration - Updated on December 15 2020 - Version 4.10.05